Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
interleukin 6
Biotech
I-Mab's IL-6 drug hits goal in ulcerative colitis phase 2
Response rates after 12 weeks of twice-monthly infusions were higher in the 600-mg arm than the placebo cohort, resulting in a p value of 0.032.
Nick Paul Taylor
Apr 26, 2021 8:45am
Lassen Therapeutics, Cedars Sinai team up on lung fibrosis work
Mar 25, 2021 9:20am
Roche test OK’d to identify high-risk COVID-19 patients
Jun 4, 2020 10:50am
